|
Lupus Erythematosus, Systemic
|
0.700 |
SusceptibilityMutation
|
disease |
ORPHANET |
We searched all the publications about the association between CTLA-4) promoter exon-1 +49 and 1722T/C polymorphism and SLE from PubMed, Elsevier Science Direct, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), and Wanfang (Chinese).
|
23922195 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus.
|
12791095 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Whether this reflects impaired downregulation by CTLA-4 molecules in SLE patients needs to be clarified further.
|
9857283 |
1998 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus.
|
12791095 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The differences in the expression of FOXP3, CTLA-4 and GITR imply the possible role of CD4(+) Tregs in the pathogenesis of SLE.
|
16423064 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that high expression of Fas, FasL and IL-6 and low expression of CTLA-4 by the CD8<sup>+</sup>CD28<sup>+</sup> T-cell subset promotes the activation-induced cell death of the CD8<sup>+</sup>CD28<sup>+</sup> T-cell subset, resulting in an imbalance of CD8<sup>+</sup>CD28<sup>-</sup>/CD8<sup>+</sup>CD28<sup>+</sup> T cells in active SLE patients, which represents an important feature in the immunological pathogenesis of SLE.
|
31399013 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
An interval encompassing the CD28-CTLA4-ICOS locus on chromosome 2q33 was linked to lupus in two genome-wide linkage scans.
|
17000707 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Multiple investigators have examined patient cohorts gathered from around the world, and although we doubt that all of the reported associations will be replicated, we have probably already discovered many of the genes that are important in lupus pathogenesis, including those encoding human leukocyte antigen-DR, Fcgamma receptor 3A, protein tyrosine phosphatase nonreceptor 22, cytotoxic T lymphocyte associated antigen 4, and mannose-binding lectin.
|
17509159 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the present study, interleukin (IL)-10-treated DCs and CTLA4-Ig were administered to mice with SLE alone or in combination and the therapeutic effects were investigated.
|
29456655 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
LHGDN |
Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus.
|
15248219 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results indicate that the non-MHC linked CTLA-4 gene could confer susceptibility in SLE, as it does in various other autoimmune diseases (Hashimoto thyroiditis, Graves' disease, IDDM).
|
10609073 |
2000 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The novelty of our study is the significance of CTLA-4 in the pathogenesis of OP besides SLE and RA.
|
23448385 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
No association was found between SLE and the CTLA-4 gene.
|
9550468 |
1998 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
LHGDN |
We characterized CD4+CD25+CTLA-4+FoxP3+ T cells in 43 patients with systemic lupus erythematosus (SLE).
|
17712998 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus.
|
31787598 |
2020 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
To determine whether 7 candidate genes, including tumor necrosis factor receptor II, bcl-2, CTLA-4, interleukin-10 (IL-10), CD19, Fcy receptor type IIA (CD32), and IL-1 receptor antagonist, may contribute to susceptibility to systemic lupus erythematosus (SLE) in the Italian population.
|
10643707 |
2000 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
We conclude that the CTLA-4 gene appears to play a significant role in the development of SLE in the Japanese population.
|
11426024 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus.
|
14522090 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings showed, that there is an association between systemic inflammatory markers, oxidative stress and the CTLA-4 G-1661A GG+AG genotypes, MDA and neopterin which are the most conventional risk factors for coronary heart disease, therefore these mutations may be consider as a risk factor for susceptibility to heart disease in SLE patients.
|
27894401 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found the first evidence of genetic association between lupus in African American patients and 5 susceptibility loci (C8orf13-BLK, BANK1, TNFSF4, KIAA1542, and CTLA4; P = 8.0 × 10⁻⁶, P = 1.9 × 10⁻⁵, P = 5.7 × 10⁻⁵, P = 0.00099, and P = 0.0045, respectively).
|
21792837 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus.
|
15248219 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, no correlation was found between CTLA-4 exon 1 (+49) and promoter (-318) polymorphisms and SLE in our study.
|
11678447 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Pathway analysis revealed several biological processes significantly associated with SLE risk: B cell receptor signaling (p = 5.28 × 10<sup>- 6</sup>), CTLA4 co-stimulation during T cell activation (p = 3.06 × 10<sup>- 5</sup>), interleukin-4 signaling (p = 3.97 × 10<sup>- 5</sup>) and cell surface interactions at the vascular wall (p = 4.63 × 10<sup>- 5</sup>).
|
29848360 |
2018 |